<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667875</url>
  </required_header>
  <id_info>
    <org_study_id>ANTON-1R21AA017525-01</org_study_id>
    <secondary_id>R21AA017525</secondary_id>
    <secondary_id>NIH Grant AA017525-01</secondary_id>
    <nct_id>NCT00667875</nct_id>
  </id_info>
  <brief_title>An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence</brief_title>
  <acronym>NALAPZ</acronym>
  <official_title>An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of this exploratory study is to examine whether the addition of
      aripiprazole to naltrexone will enhance efficacy over naltrexone alone in a 16-week
      randomized, placebo-controlled clinical trial, in which all subjects will be provided medical
      management as delivered in the COMBINE Study (Anton et al, 2006). To test whether medication
      treatment will reduce drinking compared to placebo treatment alone in the context of medical
      management and whether naltrexone plus aripiprazole will reduce drinking compared to
      naltrexone treatment alone in the context of medical management.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drinks Per Drinking Day</measure>
    <time_frame>16-week treatment period</time_frame>
    <description>Standard drinks per drinking day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Heavy Drinking Days</measure>
    <time_frame>16 weeks</time_frame>
    <description>percent of total 112 day trial in which heavy drinking occurred (&gt;=4 for females, &gt;=5 male)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pill Counts During Treatment</measure>
    <time_frame>16-week</time_frame>
    <description>Compliance with medication as determined by pill counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Riboflavin Positive Urine Samples as a Measure of Medication Compliance</measure>
    <time_frame>16 weeks treatment trial</time_frame>
    <description>Riboflavin was added to each individual capsule of medication and measured as a proxy for compliance with the medication regime</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone + Aripiprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Naltrexone (25mg or 50 mg per titration schedule)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone + Aripiprazole</intervention_name>
    <description>Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 70

          2. Subjects will meet criteria for primary alcohol dependence operationalized as follows:

             A. Meets the DSM IV criteria for alcohol dependence including loss of control over
             drinking (criterion 3) B. Has not had more than one previous inpatient medical
             detoxification

          3. Consumes, on average, at least 10 standard drinks per drinking day for men and 8
             drinks per day for women in the 90 days pre-screening (to select an appropriately
             heavy drinking population)

          4. Able to maintain sobriety for four days (with or without the aid of alcohol
             detoxification medications) as determined by self report, collateral report, and
             breathalyzer measurements

          5. Able to read and understand questionnaires and informed consent

          6. Lives within approximately 50 miles of the study site -

        Exclusion Criteria:

          1. Currently meets DSM IV criteria for any other psychoactive substance dependency
             disorder except nicotine dependence

          2. Ever abused opiates

          3. Any psychoactive substance abuse, except marijuana and nicotine, within the last 30
             days as evidenced by subject report, collateral report, or urine drug screen

          4. Meets DSM IV criteria for current axis I disorders of major depression, panic
             disorder, obsessive compulsive disorder, post traumatic stress syndrome, bipolar
             affective disorder, schizophrenia, or any other psychotic disorder or organic mental
             disorder

          5. Meets DSM IV current criteria for dissociative disorder or eating disorders

          6. Has current suicidal ideation or homicidal ideation

          7. Need for maintenance or acute treatment with any psychoactive medication including
             anti-seizure medications

          8. Current use of disulfiram

          9. Clinically significant medical problems such as cardiovascular, renal, GI, or
             endocrine problem that would impair participation or limit medication ingestion

         10. Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at
             least 3.0 times normal at screening and/or after 5 days abstinence

         11. Sexually active female of child-bearing potential who is pregnant (by urine HCG),
             nursing, or who is not using a reliable form of birth control

         12. Has current charges pending for a violent crime (not including DUI-related offenses)

         13. Does not have a stable living situation and a reliable source of collateral reporting

         14. Has taken an opiate antagonist drug in the last month

         15. Has taken aripiprazole in the last month or has experienced adverse effects from it at
             any time in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond F Anton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina, Center for Drug and Alcohol Programs</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <results_first_submitted>March 17, 2016</results_first_submitted>
  <results_first_submitted_qc>March 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2016</results_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Raymond F. Anton</investigator_full_name>
    <investigator_title>Distringuished University Professor</investigator_title>
  </responsible_party>
  <keyword>Alcohol Dependence</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Naltrexone</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Substance Abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the community in response to advertising in local papers, and radio</recruitment_details>
      <pre_assignment_details>Subjects were to remain abstinent for 4 days prior to starting treatment with the randomly assigned study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Placebo</title>
          <description>Placebo : placebo</description>
        </group>
        <group group_id="P2">
          <title>2 Naltrexone</title>
          <description>Naltrexone
Naltrexone : Naltrexone (25mg or 50 mg per titration schedule)</description>
        </group>
        <group group_id="P3">
          <title>3 Naltrexone Plus Aripiprazole</title>
          <description>Naltrexone + Aripiprazole
Naltrexone + Aripiprazole : Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23">3 subjects had no data after randomization and were excluded from analysis</participants>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21">2 subjects had no data following randomization and were excluded from the analysis.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Included in Analysisd</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13">Subjects who dropped out during treatment are considered completed if they provide end of study data</participants>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Placebo</title>
          <description>Placebo : placebo</description>
        </group>
        <group group_id="B2">
          <title>2 Naltrexone</title>
          <description>Naltrexone
Naltrexone : Naltrexone (25mg or 50 mg per titration schedule)</description>
        </group>
        <group group_id="B3">
          <title>3 Naltrexone Plus Aripiprazole</title>
          <description>Naltrexone + Aripiprazole
Naltrexone + Aripiprazole : Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="9.6"/>
                    <measurement group_id="B2" value="47.2" spread="11.3"/>
                    <measurement group_id="B3" value="48.4" spread="10.2"/>
                    <measurement group_id="B4" value="47.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drinks Per Drinking Day</title>
        <description>Standard drinks per drinking day</description>
        <time_frame>16-week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inactive Placebo</title>
            <description>Inactive placebo naltrexone + inactive placebo Aripiprazole</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone and Inactive Placebo Aripiprazole</title>
            <description>Naltrexone: Naltrexone (25mg or 50 mg per titration schedule)</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone + Aripiprazole</title>
            <description>Naltrexone + Aripiprazole: Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
          </group>
        </group_list>
        <measure>
          <title>Drinks Per Drinking Day</title>
          <description>Standard drinks per drinking day</description>
          <units>drinks per drinking day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="7.3"/>
                    <measurement group_id="O2" value="7.8" spread="6.6"/>
                    <measurement group_id="O3" value="5.2" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyzed as a mixed model, Group by time (4 time blocks) with an unstructured variance/covariance matrix. Baseline drinks per day was used as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.49</p_value>
            <p_value_desc>The p value represents variation of the total 16 week trial over all three groups.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Heavy Drinking Days</title>
        <description>percent of total 112 day trial in which heavy drinking occurred (&gt;=4 for females, &gt;=5 male)</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Placebo</title>
            <description>Placebo naltrexone and placebo aripiprazole</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone: Placebo Aripiprazole</title>
            <description>Naltrexone
Naltrexone: Naltrexone (25mg or 50 mg per titration schedule): placebo aripiprazole</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone:Aripiprazole</title>
            <description>Naltrexone + Aripiprazole
Naltrexone + Aripiprazole: Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Heavy Drinking Days</title>
          <description>percent of total 112 day trial in which heavy drinking occurred (&gt;=4 for females, &gt;=5 male)</description>
          <units>percent of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.54" spread="20.0"/>
                    <measurement group_id="O2" value="16.7" spread="19.9"/>
                    <measurement group_id="O3" value="7.34" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyzed as a mixed model (SPSS linear mixed) with an unstructured variance/covariance and baseline percent heavy drinking days as a covariate</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>The p value represents variation of the total 16 week trial over all three groups.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pill Counts During Treatment</title>
        <description>Compliance with medication as determined by pill counts</description>
        <time_frame>16-week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Placebo</title>
            <description>Placebo : placebo</description>
          </group>
          <group group_id="O2">
            <title>2 Naltrexone</title>
            <description>Naltrexone
Naltrexone : Naltrexone (25mg or 50 mg per titration schedule)</description>
          </group>
          <group group_id="O3">
            <title>3 Naltrexone Plus Aripiprazole</title>
            <description>Naltrexone + Aripiprazole
Naltrexone + Aripiprazole : Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
          </group>
        </group_list>
        <measure>
          <title>Pill Counts During Treatment</title>
          <description>Compliance with medication as determined by pill counts</description>
          <units>Percent of pills taken</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent aripiprazole or aripiprazole placebo taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" spread="6.5"/>
                    <measurement group_id="O2" value="97.0" spread="4.7"/>
                    <measurement group_id="O3" value="84.2" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent naltrexone or naltrexone placebo taken</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" spread="5.9"/>
                    <measurement group_id="O2" value="96.9" spread="4.2"/>
                    <measurement group_id="O3" value="86.4" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Anova across all three treatment groups</non_inferiority_desc>
            <p_value>&lt;.05</p_value>
            <method>ANOVA</method>
            <method_desc>Naltrexone or naltrexone placebo pills taken F=3.9 df 2 Aripiprazole or aripiprazole placebo pills taken F=4.6 df 2</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Riboflavin Positive Urine Samples as a Measure of Medication Compliance</title>
        <description>Riboflavin was added to each individual capsule of medication and measured as a proxy for compliance with the medication regime</description>
        <time_frame>16 weeks treatment trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo: Placebo</title>
            <description>Placebo naltrexone and placebo aripiprazole</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone: Placebo Aripiprazole</title>
            <description>Naltrexone
Naltrexone: Naltrexone (25mg or 50 mg per titration schedule): placebo aripiprazole</description>
          </group>
          <group group_id="O3">
            <title>Naltrexone:Aripiprazole</title>
            <description>Naltrexone + Aripiprazole
Naltrexone + Aripiprazole: Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Riboflavin Positive Urine Samples as a Measure of Medication Compliance</title>
          <description>Riboflavin was added to each individual capsule of medication and measured as a proxy for compliance with the medication regime</description>
          <units>Percent of riboflavin positive samples</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.9" spread="33.7"/>
                    <measurement group_id="O2" value="85.1" spread="18.5"/>
                    <measurement group_id="O3" value="62.1" spread="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Anova across three groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>ANOVA</method>
            <method_desc>f 3.2 df 2</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over 16 weeks following randomization visit.</time_frame>
      <desc>The SAFTEE was used to collect this data. Psychopharmacol Bull. 1986;22(2):343-81</desc>
      <group_list>
        <group group_id="E1">
          <title>Inactive Placebo</title>
          <description>Inactive placebo naltrexone + inactive placebo Aripiprazole</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone and Inactive Placebo Aripiprazole</title>
          <description>Naltrexone: Naltrexone (25mg or 50 mg per titration schedule)</description>
        </group>
        <group group_id="E3">
          <title>Naltrexone + Aripiprazole</title>
          <description>Naltrexone + Aripiprazole: Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and/or vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="20" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E3" events="14" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="15" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" events="21" subjects_affected="10" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="34" subjects_affected="14" subjects_at_risk="23"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E3" events="20" subjects_affected="9" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue or tiredness</sub_title>
                <counts group_id="E1" events="37" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E2" events="39" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E3" events="20" subjects_affected="12" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" events="33" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E3" events="28" subjects_affected="9" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness/anxiety</sub_title>
                <counts group_id="E1" events="45" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E2" events="34" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E3" events="27" subjects_affected="11" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raymond F. Anton, MD</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-1226</phone>
      <email>antonr@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

